(600223)"LUSHANG FREDA PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 600223 · · 11 pages · Chinese
Summary by 6ix AI
Notably, the cosmetics segment reported significant revenue growth, while the pharmaceutical segment faced challenges due to market policies. The report also outlines the company's ongoing efforts in product innovation and market expansion, particularly in the raw materials and additives sector.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Lushang Freda Pharmaceutical Co., Ltd. on 6ix
Earlier from Lushang Freda Pharmaceutical
- (600223)"LUSHANG FREDA PHARMACEUTICAL CO., LTD."Announcement on Appointment of Senior Executives
- (600223)"LUSHANG FREDA PHARMACEUTICAL CO., LTD."Announcement on Departure of Director and Senior Executive
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Completion of Transfer Registration of Certain Company Shares by the Controlling Shareholder through Agreement
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
Follow Lushang Freda Pharmaceutical into a list and get an email when it puts out news.
Follow Lushang Freda Pharmaceutical